Skip to main content

Poseida Therapeutics, Inc.

PSTXDelisted Jan 8, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001661460

Poseida Therapeutics, Inc. was delisted on Jan 8, 2025; its insiders filed their last Form 4 on Jan 10, 2025; 116 institutions reported holding it in 13F filings for Q4 2024, worth $519.2M in total; no superinvestor held it.

Q2 2024 vs. Q1 2024

How the institutions holding Poseida Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of PSTX: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders9193+2
Shares52.9M53.1M+209.0K (+0.4%)
Value$168.6M$154.9M−$13.7M (−8.1%)

New holders (14)

Institutions that held Poseida Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to PSTX in Q2 2024
InstitutionSharesValue% of portfolio
Mirae Asset Global ETFs Holdings Ltd.173,112$505.5K0.00%
Squarepoint Ops LLC82,637$241.3K0.00%
Corebridge Financial, Inc.36,935$107.8K0.00%
Dynamic Technology Lab Private Ltd27,031$79.0K0.01%
Prudential Financial Inc19,980$58.3K0.00%
Mackenzie Financial Corp17,616$51.4K0.00%
Principal Financial Group Inc12,006$35.1K0.00%
Graham Capital Management, L.P.11,004$32.1K0.00%
Verition Fund Management LLC10,673$31.2K0.00%
Marshall Wace, LLP10,538$30.8K0.00%
Simplex Trading, LLC1,335$3.00K0.00%
nVerses Capital, LLC800$2.34K0.00%
CWM, LLC233$1.00K0.00%
SRS Capital Advisors, Inc.38$1110.00%

Sold out (12)

Institutions that held Poseida Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.